Tixagevimab/AZD8895 represents a distinct medicinal strategy utilizing two monoclonal immunoglobulins. Specifically, these agents function by precisely binding to the receptor-binding domain of the SARS-CoV-2 agent, https://ztndz.com/story29570837/tixagevimab-azd8895-a-deep-investigation-into-its-mechanism-of-operation